Methotrexate-induced pancytopenia: Serious and under-reported? Our experience of 25 cases in 5 years

Rheumatology

Volumn 44, Issue 8, 2005, Pages 1051-1055

  Lim, Anita Y N ^a   Gaffney, K ^a   Scott, D G I ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Folic acid; Hypoalbuminaemia; Methotrexate; Mucositis; Nutritional status; Pancytopenia; Polymorphisms

Indexed keywords

ALBUMIN; AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; COCODAMOL; CODYDRAMOL; COTRIMOXAZOLE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETIDRONIC ACID; FELODIPINE; FLUOXETINE; FOLIC ACID; FOLINIC ACID; FUROSEMIDE; GLIPIZIDE; HEMOGLOBIN; LANSOPRAZOLE; METHOTREXATE; OXYBUTYNIN; PAMIDRONIC ACID; PREDNISOLONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; TEMAZEPAM; THYROXINE; UNINDEXED DRUG; ANTIRHEUMATIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; CAUSE OF DEATH; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG POTENTIATION; FACTUAL DATABASE; FEMALE; FOLIC ACID DEFICIENCY; GIANT CELL ARTERITIS; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HIP PROSTHESIS; HUMAN; HYPOALBUMINEMIA; INTERPERSONAL COMMUNICATION; KIDNEY FAILURE; LEUKOCYTE COUNT; MALE; MEDICAL RECORD; MEDICATION ERROR; PANCYTOPENIA; PATIENT SELECTION; PHARMACOGENETICS; POLYPHARMACY; PREDICTION; PRIORITY JOURNAL; PROSTHESIS INFECTION; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; THROMBOCYTE COUNT; UNITED KINGDOM; WEGENER GRANULOMATOSIS; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG INTERACTION; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PANCYTOPENIA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 24944511275     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh685     Document Type: Article

References (28)

1. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
2. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985;(Suppl 12):35-9.
3. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. Q J Med 2001;94:309-19.
4. Kremer J, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5.
5. Leeb B, Witzmann G, Ogris E et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995;13:459-63.
6. Morgan SL, Baggott JE, Refsum H, Ueland PM. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther 1991;50:547-56.
7. Van Ede AE, Laan RFJM, Rood MJ et al. Effect of folic or folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomised, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44:1515-24.
8. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD000951.
9. Weinblatt ME, Kaplan H, Germain BF et al. Low dose methotrexate compared with auranofin in adult rheumatoid arthritis: A thirty-six-week, double-blind trial. Arthritis Rheum 1992;35:330-8.
10. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159: 2542-50.
11. Eting LS, Bodey GP, Keefe BH. Septicaemia and shock syndrome due to viridans streptococci: A case control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.
12. Peterson DE. Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monogr 1990;9:61-71.
13. Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA. Formation of methotrexate polyglutamates in purified myeloid precursors cells from normal human bone marrow. J Clin Invest 1985;75:1008-14.
14. Rosenblatt DS, Whitehead VM, Dupont MM, Vuchich MJ, Vera N. Synthesis of methotrexate polyglutamates in cultured human cells. Mol Pharmacol 1978;14:210-4.
15. Shin YS, Buehring KU, Stokstad ELR. The metabolism of methotrexate in Lactobacillus casei and rat liver and the influence of methotrexate on metabolism of folic acid. J Biol Chem 1974;249:5772.
16. Rajeswari R, Shetty PA, Gothoskar BP et al. Pharmacokinetics of methotrexate in adult Indian patients and its relationship to nutritional status. Cancer Treat Rep 1984;68:727.
17. Mihranian MH, Wang YM, Daly JM. Effects of nutritional depletion and repletion on plasma methotrexate pharmacokinetics. Cancer 1984;52:2268.
18. Buchbinder R, Hall S, Sambrook PN et al. Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice. J Rheumatol 1993;20:639-44.
19. Hendel J, Nyfors A. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Eur J Clin Pharmacol 1984;26:121-4.
20. Songsiridej N, Furst DE. Methotrexate - the rapidly acting drug. Baillieres Clin Rheumatol 1990;4:575-93.
21. Coleiro B, Mallia C. Toxicity profile of methotrexate in rheumatoid arthritis. A preliminary study. Adv Exp Med Biol 1999;455:359-65.
22. Bleyer WA. The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 1978;41:36-51.
23. Van Ede AE, Laan RFJM, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
24. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-4.
25. Toffoli G, Veronesi A, Boiocchi M. Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate and fluorouracil (CMF). Ann Oncol 2000;11:373-4.
26. Berkun Y, Levartovsky D, Rubinow A et al. Methotrexate related adverse effects in patients with rheumatoid arthritis, are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004;63:1227-31.
27. Kolte B, Baer AN, Sait SN et al. Acute myeloid leukaemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis. Leuk Lymphoma 2001;42:371-8.
28. Skibola CF, Smith MT, Kane E et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukaemia in adults. Proc Natl Acad Sci USA 1999;96:12810-5.